7 results on '"Glass, Bertram"'
Search Results
2. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma.
- Author
-
Borgerding, Andrea, Hasenkamp, Justin, Glaß, Bertram, Wulf, Gerald, Trümper, Lorenz, Glass, Bertram, and Trümper, Lorenz
- Subjects
RITUXIMAB ,ANTINEOPLASTIC agents ,MONOCLONAL antibodies ,B cell lymphoma ,LYMPHOMAS - Abstract
Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line immunochemotherapy with rituximab. In 28 patients with relapsed or refractory diffuse large B cell lymphomas, first-line immunochemotherapy had induced objective responses in 18 patients. Nine of 28 patients responded to rituximab containing salvage therapy, leading to a median overall survival of 243 days after start of second immunochemotherapy. Long-term disease free survivors (1,260 and 949 days) were restricted to the group of twelve patients that had received allogeneic stem cell transplantation as consolidation therapy. In 21 patients with relapsed mantle cell lymphomas (MCL), 19 patients had reached remissions with first-line therapy. Of those, 16 patients experienced responses to salvage therapy with a median overall survival of 226 days. Noteworthy, none of patients with initial non-responding disease reached a remission with second immunochemotherapy. Seven patients with MCL stayed free from progression after high-dose therapy with autologous or allogeneic stem cell transplantation in two and five cases, respectively. In summary, responses to repeated immunotherapy with rituximab were observed in approximately one third and two thirds of initially responding patients with aggressive B cell lymphoma and mantle cell lymphoma, respectively, but not in primarily refractory disease. Lasting remissions were achieved only by high-dose chemotherapy with stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
3. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
- Author
-
Glass, Bertram, Hasenkamp, Justin, Wulf, Gerald, Dreger, Peter, Pfreundschuh, Michael, Gramatzki, Martin, Silling, Gerda, Wilhelm, Christian, Zeis, Matthias, Görlitz, Anke, Pfeiffer, Sebastian, Hilgers, Reinhard, Truemper, Lorenz, and Schmitz, Norbert
- Subjects
- *
RITUXIMAB , *STEM cell transplantation , *HOMOGRAFTS , *LYMPHOMAS , *ANTIBIOTIC prophylaxis , *GRAFT versus host disease , *RANDOMIZED controlled trials - Abstract
Summary: Background: Allogeneic stem-cell transplantation has had limited success for patients with refractory and relapsed aggressive B-cell or T-cell lymphoma. We investigated the effect of adding rituximab to standard prophylaxis for graft-versus-host disease after transplantation and estimated overall survival when using a lymphoma-directed myeloablative conditioning regimen. Methods: We did this randomised, open-label, phase 2 study at seven German transplantation centres. We enrolled patients with aggressive B-cell or T-cell lymphoma and primary refractory disease, early relapse (<12 months after first-line treatment), or relapse after autologous transplantation. Conditioning with fludarabine (125 mg/m2), busulfan (12 mg/kg oral or 9·6 mg/kg intravenous), and cyclophosphamide (120 mg/kg) was followed by allogeneic stem-cell transplantation. Patients were randomly assigned (1:1) to receive rituximab (375 mg/m2 on days 21, 28, 35, 42, 175, 182, 189, and 196) or not. Allocation was done with a centralised computer-generated procedure; patients were stratified by histological subtype (B-cell vs T-cell lymphoma) and donor match (HLA-identical vs non-identical). Neither investigators nor patients were masked to allocation. The primary endpoints were the incidence of acute graft-versus-host disease grade 2–4 in each treatment group and overall survival at 1 year in both groups combined. All analyses were done for the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00785330. Findings: Between June 16, 2004, and March 24, 2009, we screened 86 patients and enrolled 84; 42 were randomly assigned to each group. The cumulative incidence of grade 2–4 acute graft-versus-host disease was 46% (95% CI 32–62) in the rituximab group and 42% (95% CI 29–59) in the no rituximab group (hazard ratio [HR] 0·91, 95% CI 0·52–1·60; p=0·74). Overall survival at 1 year for the whole study population was 52% (95% CI 41–62). Grade 4 haematological toxic effects and grade 3 alopecia occurred in all patients. The most common non-haematological grade 5 toxic effects were pneumonia (nine in the no rituximab group vs ten in the rituximab group) and other infections (seven vs four). Interpretation: The lymphoma-directed myeloablative conditioning regimen developed here is promising for patients with refractory and relapsed aggressive B-cell and T-cell lymphomas. However, the addition of rituximab did not affect the incidence of graft-versus-host disease or overall survival. Funding: Hoffmann-La Roche, Amgen, Astellas Pharma. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-anti-CD20 antibody and stem cell rescue.
- Author
-
Hohloch, Karin, Sahlmann, Carsten, Lakhani, Vijai, Wulf, Gerald, Glaß, Bertram, Hasenkamp, Justin, Meller, Johannes, Riggert, Joachim, Trümper, Lorenz, and Griesinger, Frank
- Subjects
STEM cell transplantation research ,RADIOIMMUNOTHERAPY ,RITUXIMAB ,B cells ,DISEASE progression ,LYMPHOMAS ,SALVAGE therapy ,PNEUMONIA - Abstract
A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-anti-CD20 antibody (I-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed ( n = 14) and refractory ( n = 2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 ( n = 4), transformed follicular (FL 3b; n = 6), diffuse large B-cell (DLBCL; n = 4), mantle cell ( n = 1) and marginal zone lymphoma ( n = 1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells.
- Author
-
Hasenkamp, Justin, Borgerding, Andrea, Wulf, Gerald, Schmitz, Norbert, Truemper, Lorenz, and Glass, Bertram
- Subjects
KILLER cells ,APOPTOSIS ,CELLULAR therapy ,CELLULAR immunity ,TRANSPLANTATION of organs, tissues, etc. ,RESEARCH ,PROTEASE inhibitors ,ANIMAL experimentation ,RESEARCH methodology ,IMMUNOLOGY technique ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,IMMUNITY ,LYMPHOMAS ,CELL lines ,MICE ,PHARMACODYNAMICS - Abstract
Natural killer (NK) cells contribute to the graft-versus-leukemia effect after allogeneic stem cell transplantation. However, the efficacy of NK cell-mediated tumor cell lysis is limited due to target cell resistance, and target cell-induced apoptosis (TiA) was proposed to contribute to differences in susceptibility to NK cells. Here we analyzed the effects of target cells on the apoptosis of cytokine-activated NK cells in vitro. We found no association of target cell susceptibility and TiA of NK cells in an array of human and murine target-effector cell combinations. Incubation of NK cells with caspase inhibitors blocked TiA incompletely, indicating that TiA is partly based on caspase-independent mechanisms. Modulating NK cell susceptibility against TiA by caspase inhibition did not influence cytotoxic efficacy. Furthermore, we found cytotoxic potential of NK cells to be markedly decreased following first target cell contact. Exhaustion of NK cell activity by first target cell contact was, however, not mediated by TiA. In addition, we found no relevant TiA by lymphoma cell lines against activated murine NK cells. We conclude that TiA represents only a minor factor of target cell resistance against NK cell-mediated cytolysis. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
6. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma.
- Author
-
Basecke, Jorg, Podleschny, Martina, Becker, Annegret, Seiffert, Edda, Schwiers, Ivonne, Schwiers, Roman, Haase, Detlef, Glass, Bertram, Schmitz, Norbert, Trumper, Lorenz, and Griesinger, Frank
- Subjects
CHROMOSOME abnormalities ,LYMPHOMAS ,MYELODYSPLASTIC syndromes ,ACUTE myeloid leukemia ,DRUG therapy ,CYTOGENETICS - Abstract
Therapy-associated myelodysplastic syndromes and acute myeloid leukaemia (t-AML/MDS) following high dose chemotherapy are significant problems, with a cumulative incidence of 20% or more in myeloablative treatment regimen. Retrospective findings indicated that t-AML/MDS associated genetic aberrations can be observed directly after exposure to chemotherapy and can precede t-AML by several months. To determine the incidence of post-therapeutic aberrations and their predictive value, we prospectively investigated 316 samples of 95 patients with non-Hodgkin lymphoma (NHL) who were treated with intermediate and high dose chemotherapy (Arm A and B of the megaCHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisolone) trial of the German High Grade NHL study group). Molecular aberrations ( RUNX1/RUNX1T1, PML-RARA, CBFB-MYH11, MLL-MLLT1, BCR-ABL1) were observed in 33·3% (Arm A) and 55·4% (Arm B) of patients and in 14·9% and 28·7% of respective samples. Cytogenetic analysis of 53 NHL patients after high dose therapy showed frequent chromosomal breakage. Clonal aberrations were found in three patients. None of these patients developed a t-AML/MDS during a 3-year clinical follow up period. We concluded that the high incidence of genetic aberrations reflected a dose-dependent, transient therapy-induced genetic damage which is not predictive of a t-AML/MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
7. Therapeutic strategies for agressive lymphomas: The trials of the DSHNHL.
- Author
-
Schmits, Rudolf, Glass, Bertram, Trümper, Lorenz, and Pfreundschuh, Michael
- Subjects
LYMPHOMAS ,DRUG therapy ,LYMPHOPROLIFERATIVE disorders ,DRUGS ,PHOTOTHERAPY ,THERAPEUTICS - Abstract
This article presents information related to the therapeutic strategies for aggressive lymphomas. Aggressive non-Hodgkin's lymphomas are highly radiosensitive and doses between 36 Gy and 45 Gy appear to be sufficient for the eradication of the malignant clone. Consolidation radiotherapy given in addition to full-cycle chemotherapy is a frequent practice, unfortunately based on limited data. The identification of factors underlying the patient selection in oligocentre trials became of prime importance, since it was obviously a prerequisite for a better understanding of the factors determining the success and failure of chemotherapy.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.